Lara Lewis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lara Lewis has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Jienchi Dorward
Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu–Natal, Durban, South Africa
21 shared publications - Nigel Garrett
Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
14 shared publications Thokozani Khubone
Thekwini Municipality Health Unit
13 shared publicationsJohan van der Molen
Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu–Natal, Durban, South Africa
10 shared publications- Yukteshwar Sookrajh
Thekwini Municipality Health Unit
10 shared publications - Kwena Tlhaku
Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa
9 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0005506
Trends in advanced HIV disease, treatment interruption, and viraemia in KwaZulu-Natal, South Africa
Advanced HIV disease (AHD), treatment interruption and viraemia remain key challenges to effectiveness of HIV programmes in South Africa. Understanding the trends of these measures and their variation across geographic regions can inform more targeted and responsive interventions. We conducted a retrospective cohort study using routine, de-identified data from TIER.Net, a national HIV electronic register. We curated data from 116 primary care clinics in eThekwini, uMgungudlovu, and uMkhanyakude Districts in KwaZulu-Natal province. We included people living with HIV aged ≥16 years, who initiated or collected ART between 1 July 2018 and 30 June 2023. We examined trends in the annual clinic-level prevalence of AHD, treatment interruption and viraemia, and mapped these outcomes using inverse distance weighted interpolation restricted to 3 nearest neighbours to preserve local influence. Among 123,473 clients initiating ART with CD4 count measurements, the overall prevalence of AHD ranged between 20.0% and 22.2%. The prevalence of treatment interruptions ranged between 11.3% and 13.2% among the 544,066 clients who had scheduled visits. Of the 446,899 clients who had viral load results, overall viraemia, defined as ≥50 copies/mL, increased from 12.9% to 20.2%, whereas high-level viraemia defined as ≥1000 copies/mL remained stable at approximately 6%. Spatial analyses highlighted geographic disparities in AHD, treatment interruption, and viraemia across and within the districts. The persistence of AHD, treatment interruption and viraemia require further investigation and highlight ongoing challenges for HIV control. The observed spatial variation across and within districts spanning urban, peri-urban and rural settings highlight the need for geographically tailored interventions to improve programmatic effectiveness, particularly in hyper-endemic settings.
- 2 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0005506
Open AccessTrends in advanced HIV disease, treatment interruption, and viraemia in KwaZulu-Natal, South Africa
Advanced HIV disease (AHD), treatment interruption and viraemia remain key challenges to effectiveness of HIV programmes in South Africa. Understanding the trends of these measures and their variation across geographic regions can inform more targeted and responsive interventions. We conducted a retrospective cohort study using routine, de-identified data from TIER.Net, a national HIV electronic register. We curated data from 116 primary care clinics in eThekwini, uMgungudlovu, and uMkhanyakude Districts in KwaZulu-Natal province. We included people living with HIV aged ≥16 years, who initiated or collected ART between 1 July 2018 and 30 June 2023. We examined trends in the annual clinic-level prevalence of AHD, treatment interruption and viraemia, and mapped these outcomes using inverse distance weighted interpolation restricted to 3 nearest neighbours to preserve local influence. Among 123,473 clients initiating ART with CD4 count measurements, the overall prevalence of AHD ranged between 20.0% and 22.2%. The prevalence of treatment interruptions ranged between 11.3% and 13.2% among the 544,066 clients who had scheduled visits. Of the 446,899 clients who had viral load results, overall viraemia, defined as ≥50 copies/mL, increased from 12.9% to 20.2%, whereas high-level viraemia defined as ≥1000 copies/mL remained stable at approximately 6%. Spatial analyses highlighted geographic disparities in AHD, treatment interruption, and viraemia across and within the districts. The persistence of AHD, treatment interruption and viraemia require further investigation and highlight ongoing challenges for HIV control. The observed spatial variation across and within districts spanning urban, peri-urban and rural settings highlight the need for geographically tailored interventions to improve programmatic effectiveness, particularly in hyper-endemic settings.
- Open Access
Effect of transitioning virally suppressed children and adolescents with HIV to dolutegravir-based antiretroviral therapy: emulated target trials in a large cohort in South Africa
Background: Global HIV programmes are transitioning virally suppressed children and adolescents with HIV (CAWH) from prior regimens to dolutegravir-based antiretroviral therapy (ART). However, the supporting evidence largely stems from randomised trials in viraemic CAWH. The effect of transition for virally suppressed CAWH is unknown. Methods: We used observational, de-identified data from 724 clinics in KwaZulu-Natal, South Africa. We sequentially emulated three distinct target trials to estimate the effect of transitioning to dolutegravir-based ART in three paediatric populations: i) ages 8-17 years taking efavirenz-based ART, ii) 8-17 years taking ritonavir-boosted lopinavir (LPV/r)-based ART, and iii) 0-7 years taking LPV/r-based ART, all with a last viral load 1,000 copies/mL through 12 and 24 months was estimated using an inverse probability weighting approach. Findings: From January 2020 to August 2024, 37,145 CAWH contributed 454,081 person-trials. In CAWH initially taking efavirenz, the standardised 12-month risk of death or viraemia was 11·9% with continued efavirenz and 6·7% with transition to dolutegravir (RD -5·2 [95% CI -5·8 to -4·6]). In older CAWH initially taking LPV/r, these risks were 17·8% and 9·5%, respectively (RD -8·3 [-10·0 to -6·8]). In younger children, the respective risks were 15·8% and 6·7% (RD -9·0% [-12·7 to -5·4]). Where available, 24-month endpoints showed slightly greater RDs. Interpretation: This large-scale, causal analysis highlights improvements in viral suppression and strongly supports ongoing transition to dolutegravir-based ART for virally suppressed CAWH. Funding: Gates Foundation, National Institute for Health and Care Research, Swiss National Science Foundation Research in context: Evidence before this study: We searched PubMed on 23 June 2026 for randomised controlled trials or trial emulations comparing dolutegravir (DTG)-based antiretroviral therapy (ART) with non-DTG-based ART among children and adolescents with HIV (CAWH). The search string is shown in Table S1. Two major trials, ODYSSEY and CHAPAS-4, compared DTG-based with non-DTG-based ART regimens among CAWH with viraemia (i.e. newly starting first-line ART or switching to second-line ART after treatment failure with a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen). Both trials showed better treatment outcomes with DTG-based ART, informing the ongoing programmatic rollout of DTG-based ART for CAWH. In practice, the majority of CAWH eligible for DTG will be virally suppressed on a non-DTG regimen, a group which was not included in ODYSSEY and CHAPAS-4. To date, there is a lack of empirical evidence demonstrating outcomes after paediatric transition to DTG in case of viral suppression. On the one hand, unnecessary ART modification may disrupt adherence; on the other hand, DTG-based ART may be favourable considering the complexity and unpalatability of some prior standard of care regimens. Therefore, there is a need to evaluate the causal effect of transitioning to DTG-based ART in case of viral suppression, specifically among CAWH as a priority group for improving treatment outcomes. Added value of this study: Here, we compared treatment outcomes among three distinct paediatric groups in the South African HIV programme who became eligible to transition to DTG-based ART at different time points: older CAWH initially taking efavirenz (EFV)-based ART, older CAWH initially taking ritonavir-boosted lopinavir (LPV/r)-based ART, and young children initially taking LPV/r-based ART. To our knowledge, this study of 38,041 CAWH is the largest clinical cohort of CAWH receiving DTG and presents the first estimate on the effect of transitioning to DTG-based ART among CAWH with viral suppression. Across all groups, the standardised cumulative risk of death or viraemia was lowered by switching to ART containing DTG compared with remaining on the former standard of care, with risk differences (RDs) ranging from -5·2% to -9·0% at 12 months and increasing over follow-up time. Implications of all the available evidence: We observed substantial improvements in treatment outcomes with transition to DTG. These findings strongly support the continued transition to DTG-based ART among virally suppressed CAWH.
Open AccessEffect of transitioning virally suppressed children and adolescents with HIV to dolutegravir-based antiretroviral therapy: emulated target trials in a large cohort in South Africa
Background: Global HIV programmes are transitioning virally suppressed children and adolescents with HIV (CAWH) from prior regimens to dolutegravir-based antiretroviral therapy (ART). However, the supporting evidence largely stems from randomised trials in viraemic CAWH. The effect of transition for virally suppressed CAWH is unknown. Methods: We used observational, de-identified data from 724 clinics in KwaZulu-Natal, South Africa. We sequentially emulated three distinct target trials to estimate the effect of transitioning to dolutegravir-based ART in three paediatric populations: i) ages 8-17 years taking efavirenz-based ART, ii) 8-17 years taking ritonavir-boosted lopinavir (LPV/r)-based ART, and iii) 0-7 years taking LPV/r-based ART, all with a last viral load 1,000 copies/mL through 12 and 24 months was estimated using an inverse probability weighting approach. Findings: From January 2020 to August 2024, 37,145 CAWH contributed 454,081 person-trials. In CAWH initially taking efavirenz, the standardised 12-month risk of death or viraemia was 11·9% with continued efavirenz and 6·7% with transition to dolutegravir (RD -5·2 [95% CI -5·8 to -4·6]). In older CAWH initially taking LPV/r, these risks were 17·8% and 9·5%, respectively (RD -8·3 [-10·0 to -6·8]). In younger children, the respective risks were 15·8% and 6·7% (RD -9·0% [-12·7 to -5·4]). Where available, 24-month endpoints showed slightly greater RDs. Interpretation: This large-scale, causal analysis highlights improvements in viral suppression and strongly supports ongoing transition to dolutegravir-based ART for virally suppressed CAWH. Funding: Gates Foundation, National Institute for Health and Care Research, Swiss National Science Foundation Research in context: Evidence before this study: We searched PubMed on 23 June 2026 for randomised controlled trials or trial emulations comparing dolutegravir (DTG)-based antiretroviral therapy (ART) with non-DTG-based ART among children and adolescents with HIV (CAWH). The search string is shown in Table S1. Two major trials, ODYSSEY and CHAPAS-4, compared DTG-based with non-DTG-based ART regimens among CAWH with viraemia (i.e. newly starting first-line ART or switching to second-line ART after treatment failure with a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen). Both trials showed better treatment outcomes with DTG-based ART, informing the ongoing programmatic rollout of DTG-based ART for CAWH. In practice, the majority of CAWH eligible for DTG will be virally suppressed on a non-DTG regimen, a group which was not included in ODYSSEY and CHAPAS-4. To date, there is a lack of empirical evidence demonstrating outcomes after paediatric transition to DTG in case of viral suppression. On the one hand, unnecessary ART modification may disrupt adherence; on the other hand, DTG-based ART may be favourable considering the complexity and unpalatability of some prior standard of care regimens. Therefore, there is a need to evaluate the causal effect of transitioning to DTG-based ART in case of viral suppression, specifically among CAWH as a priority group for improving treatment outcomes. Added value of this study: Here, we compared treatment outcomes among three distinct paediatric groups in the South African HIV programme who became eligible to transition to DTG-based ART at different time points: older CAWH initially taking efavirenz (EFV)-based ART, older CAWH initially taking ritonavir-boosted lopinavir (LPV/r)-based ART, and young children initially taking LPV/r-based ART. To our knowledge, this study of 38,041 CAWH is the largest clinical cohort of CAWH receiving DTG and presents the first estimate on the effect of transitioning to DTG-based ART among CAWH with viral suppression. Across all groups, the standardised cumulative risk of death or viraemia was lowered by switching to ART containing DTG compared with remaining on the former standard of care, with risk differences (RDs) ranging from -5·2% to -9·0% at 12 months and increasing over follow-up time. Implications of all the available evidence: We observed substantial improvements in treatment outcomes with transition to DTG. These findings strongly support the continued transition to DTG-based ART among virally suppressed CAWH.
- Open Access
An audit assessing data quality, viral suppression, and transition to dolutegravir among children and adolescents with HIV in care at eThekwini Municipality, South Africa
Background: The 2023 South African antiretroviral therapy (ART) guidelines recommend dolutegravir-based ART for children and adolescents with HIV (CAWH) >4 weeks old, including transition to dolutegravir-based ART if previously taking another regimen. Objectives: We audited uptake of dolutegravir-based ART, viral load (VL) testing, and viral suppression among CAWH in care in eThekwini, South Africa. We also aimed to assess and improve the quality of routinely collected ART and VL data in the national HIV electronic register (TIER.Net) in this population. Methods: We used TIER.Net line lists to identify CAWH aged ≤19 years in care in 54 eThekwini Municipality clinics between February and July 2025. CAWH who had died, transferred out, or were lost to follow-up were excluded. We reviewed clinical files and TIER.Net records simultaneously to compare all recorded ART regimens and recent (last 12 months) VL results. High or missing VLs were flagged for medical review, and data discrepancies were corrected. Results: Among 3838 eligible CAWH, we reviewed files of 3379 (88%). 1991 (59%) were female and 2812 (83%) were aged 10-19 years. All 3379 (100%) were receiving dolutegravir-based ART. 193 (6%) had no recent VL result. Of those who did, 303 (10%) had a last VL ≥1000 copies/mL. We identified 941 (28%), 438 (13%), and 199 (6%) TIER.Net data capture errors for ART regimens, ART regimen start/stop dates, or recent VLs, respectively. Conclusion: This audit at 54 facilities showed complete transition to dolutegravir among reviewed files of CAWH in care, but highlighted gaps in viral suppression and documentation.
Open AccessAn audit assessing data quality, viral suppression, and transition to dolutegravir among children and adolescents with HIV in care at eThekwini Municipality, South Africa
Background: The 2023 South African antiretroviral therapy (ART) guidelines recommend dolutegravir-based ART for children and adolescents with HIV (CAWH) >4 weeks old, including transition to dolutegravir-based ART if previously taking another regimen. Objectives: We audited uptake of dolutegravir-based ART, viral load (VL) testing, and viral suppression among CAWH in care in eThekwini, South Africa. We also aimed to assess and improve the quality of routinely collected ART and VL data in the national HIV electronic register (TIER.Net) in this population. Methods: We used TIER.Net line lists to identify CAWH aged ≤19 years in care in 54 eThekwini Municipality clinics between February and July 2025. CAWH who had died, transferred out, or were lost to follow-up were excluded. We reviewed clinical files and TIER.Net records simultaneously to compare all recorded ART regimens and recent (last 12 months) VL results. High or missing VLs were flagged for medical review, and data discrepancies were corrected. Results: Among 3838 eligible CAWH, we reviewed files of 3379 (88%). 1991 (59%) were female and 2812 (83%) were aged 10-19 years. All 3379 (100%) were receiving dolutegravir-based ART. 193 (6%) had no recent VL result. Of those who did, 303 (10%) had a last VL ≥1000 copies/mL. We identified 941 (28%), 438 (13%), and 199 (6%) TIER.Net data capture errors for ART regimens, ART regimen start/stop dates, or recent VLs, respectively. Conclusion: This audit at 54 facilities showed complete transition to dolutegravir among reviewed files of CAWH in care, but highlighted gaps in viral suppression and documentation.
- Open Access
Diagnostic accuracy of point-of-care urine tenofovir test, and associations between metrics of tenofovir use and treatment outcomes in a community ART programme
Background: Urine tenofovir (uTFV) and dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations respectively estimate short- and medium-term adherence to tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART). We evaluated the accuracy of a point-of-care uTFV assay, and associations between uTFV/TFV-DP, and viral load (VL) and retention outcomes within a South African community ART programme. Methods: We measured uTFV and DBS TFV-DP concentrations using liquid chromatography-tandem mass spectrometry (LC-MS/MS). We calculated sensitivity and specificity of the point-of-care uTFV assay at the manufacturer-recommended threshold of ≥1,500 ng/mL compared to LC-MS/MS. We assessed associations of the point-of-care uTFV assay, and DBS TFV-DP concentrations with concurrent viraemia, and with retention-in-care by 16 weeks post-enrolment. Results: Of 196 adults median age was 44 years, 127 (64.8%) were female, and 191 (97.4%) were receiving TDF. 185 (94.4%) had detectable point-of-care uTFV, which had high sensitivity (99.5%, 95% CI 96.5-100%) and moderate specificity (76.9%, 95% CI 46.0-93.8%) for detecting uTFV ≥1,500 ng/mL. Two participants had concurrent viraemia ≥1,000 copies/mL; of these 50.0% (95% CI 9.4-90.5) had undetectable point-of-care uTFV, and 100% (95% CI 19.7-100) had low TFV-DP <483 fmol/punch. Among participants without viraemia 97.4% (95% CI 93.6-99.0) had detectable uTFV, and 98.1% (95.3-99.6) had high TFV-DP ≥483 fmol/punch. Point-of-care uTFV and DBS TFV-DP were not associated with retention-in-care. Conclusions: The point-of-care uTFV assay demonstrated high sensitivity and moderate specificity to detect uTFV. Over 95% of people without viraemia had detectable point-of-care uTFV or high DBS TFV-DP levels respectively, but these were not associated with 16-week retention-in-care.
Open AccessDiagnostic accuracy of point-of-care urine tenofovir test, and associations between metrics of tenofovir use and treatment outcomes in a community ART programme
Background: Urine tenofovir (uTFV) and dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations respectively estimate short- and medium-term adherence to tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART). We evaluated the accuracy of a point-of-care uTFV assay, and associations between uTFV/TFV-DP, and viral load (VL) and retention outcomes within a South African community ART programme. Methods: We measured uTFV and DBS TFV-DP concentrations using liquid chromatography-tandem mass spectrometry (LC-MS/MS). We calculated sensitivity and specificity of the point-of-care uTFV assay at the manufacturer-recommended threshold of ≥1,500 ng/mL compared to LC-MS/MS. We assessed associations of the point-of-care uTFV assay, and DBS TFV-DP concentrations with concurrent viraemia, and with retention-in-care by 16 weeks post-enrolment. Results: Of 196 adults median age was 44 years, 127 (64.8%) were female, and 191 (97.4%) were receiving TDF. 185 (94.4%) had detectable point-of-care uTFV, which had high sensitivity (99.5%, 95% CI 96.5-100%) and moderate specificity (76.9%, 95% CI 46.0-93.8%) for detecting uTFV ≥1,500 ng/mL. Two participants had concurrent viraemia ≥1,000 copies/mL; of these 50.0% (95% CI 9.4-90.5) had undetectable point-of-care uTFV, and 100% (95% CI 19.7-100) had low TFV-DP <483 fmol/punch. Among participants without viraemia 97.4% (95% CI 93.6-99.0) had detectable uTFV, and 98.1% (95.3-99.6) had high TFV-DP ≥483 fmol/punch. Point-of-care uTFV and DBS TFV-DP were not associated with retention-in-care. Conclusions: The point-of-care uTFV assay demonstrated high sensitivity and moderate specificity to detect uTFV. Over 95% of people without viraemia had detectable point-of-care uTFV or high DBS TFV-DP levels respectively, but these were not associated with 16-week retention-in-care.
- 11 August 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , 609-619
Geographic Variation in Diagnostic Performance of Amsel Criteria and Nugent Score for Vaginal Dysbiosis Defined by 16S rRNA Gene Sequencing
Background: Vaginal dysbiosis characterized by low abundance of vaginal lactobacilli and increased bacterial community diversity, is implicated in multiple adverse health outcomes and is an emerging target for preventive interventions, including live biotherapeutic products. The most common clinical presentation of vaginal dysbiosis is bacterial vaginosis (BV), but at least half of people are asymptomatic. Methods: We compared identification of BV by Nugent score and Amsel criteria for screening specimens from a Phase 1b randomized trial of a live biotherapeutic product conducted at 2 sites (CAPRISA, South Africa; MGH, USA), as well as a single follow-up visit from enrolled participants. Using 16S rRNA gene sequencing-based categorization of community state type (CST) as the reference and multinomial mixed-effects logistic models, we evaluated the association of Amsel BV and Nugent BV with CST IV (including subtypes IV-A and IV-B) and tested for site-specific effects. Results: Amsel BV was significantly associated with CST IV-A and IV-B; however, the strength of association was significantly diminished at CAPRISA compared with MGH, pointing to site-specific assessment differences or underlying biological variation. Nugent BV yielded stronger associations with CST IV-A, and IV-B and showed no evidence of a site-specific interaction, indicating consistent performance across sites. Conclusions: These findings indicate that diagnostic performance for vaginal dysbiosis varies by framework: Amsel criteria are more susceptible to geographical site effects, whereas Nugent score demonstrates stronger and more site-agnostic associations. For clinical studies targeting vaginal dysbiosis, Nugent scoring and/or sequencing-based approaches should be prioritized for vaginal dysbiosis endpoint definition and stratification.
- 11 August 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , 609-619
Geographic Variation in Diagnostic Performance of Amsel Criteria and Nugent Score for Vaginal Dysbiosis Defined by 16S rRNA Gene Sequencing
Background: Vaginal dysbiosis characterized by low abundance of vaginal lactobacilli and increased bacterial community diversity, is implicated in multiple adverse health outcomes and is an emerging target for preventive interventions, including live biotherapeutic products. The most common clinical presentation of vaginal dysbiosis is bacterial vaginosis (BV), but at least half of people are asymptomatic. Methods: We compared identification of BV by Nugent score and Amsel criteria for screening specimens from a Phase 1b randomized trial of a live biotherapeutic product conducted at 2 sites (CAPRISA, South Africa; MGH, USA), as well as a single follow-up visit from enrolled participants. Using 16S rRNA gene sequencing-based categorization of community state type (CST) as the reference and multinomial mixed-effects logistic models, we evaluated the association of Amsel BV and Nugent BV with CST IV (including subtypes IV-A and IV-B) and tested for site-specific effects. Results: Amsel BV was significantly associated with CST IV-A and IV-B; however, the strength of association was significantly diminished at CAPRISA compared with MGH, pointing to site-specific assessment differences or underlying biological variation. Nugent BV yielded stronger associations with CST IV-A, and IV-B and showed no evidence of a site-specific interaction, indicating consistent performance across sites. Conclusions: These findings indicate that diagnostic performance for vaginal dysbiosis varies by framework: Amsel criteria are more susceptible to geographical site effects, whereas Nugent score demonstrates stronger and more site-agnostic associations. For clinical studies targeting vaginal dysbiosis, Nugent scoring and/or sequencing-based approaches should be prioritized for vaginal dysbiosis endpoint definition and stratification.
- Open Access
- 22 June 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (10) , 1133-1139
Indirect effects of HIV differentiated service delivery programmes on quality of clinic care: a retrospective cohort study of clients starting antiretroviral therapy
Background: While the benefits for clients collecting antiretroviral therapy (ART) through differentiated service delivery programmes (DSD) have been described, there are limited data on whether DSD indirectly benefits clients ineligible for DSD, by allowing more clinic resources to be redirected towards them. Setting: De-identified, routinely-collected data from 112 clinics in KwaZulu-Natal, South Africa were analysed. Methods: Using generalized linear mixed effects regression, we assessed whether the quality of care provided to clients initiating ART (and therefore ineligible for DSD) improved following increases in the proportion of clients in their clinic referred to DSD. Quality-of-care outcomes were the probability of clients having a CD4 count test, having a 6-month viral load (VL) test and being retained for 6 months. Results: Between February 2022 and September 2023, 36,865 clients initiated ART. Among those in each outcome analysis, 77% had CD4 count results, 72% had 6-month VL results, and 70% were retained for 6 months. We found a positive relationship between the clinic DSD referral proportion and test completion among newly initiated clients, although this was only weakly significant for CD4 count; when DSD referrals increased from 20-30%, the probability of having a CD4 count and VL test increased by 0.97% (95% CI: -0.27,2.58%) and 1.35% (95% CI: 0.11,2.95%) respectively. We found no evidence of an association with DSD and retention. Conclusions: In the first study of this topic, increases in clinic DSD referrals were associated with small improvements in care. With full DSD scale-up, programmatically meaningful effects could be achieved.
- 22 June 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (10) , 1133-1139
Open AccessIndirect effects of HIV differentiated service delivery programmes on quality of clinic care: a retrospective cohort study of clients starting antiretroviral therapy
Background: While the benefits for clients collecting antiretroviral therapy (ART) through differentiated service delivery programmes (DSD) have been described, there are limited data on whether DSD indirectly benefits clients ineligible for DSD, by allowing more clinic resources to be redirected towards them. Setting: De-identified, routinely-collected data from 112 clinics in KwaZulu-Natal, South Africa were analysed. Methods: Using generalized linear mixed effects regression, we assessed whether the quality of care provided to clients initiating ART (and therefore ineligible for DSD) improved following increases in the proportion of clients in their clinic referred to DSD. Quality-of-care outcomes were the probability of clients having a CD4 count test, having a 6-month viral load (VL) test and being retained for 6 months. Results: Between February 2022 and September 2023, 36,865 clients initiated ART. Among those in each outcome analysis, 77% had CD4 count results, 72% had 6-month VL results, and 70% were retained for 6 months. We found a positive relationship between the clinic DSD referral proportion and test completion among newly initiated clients, although this was only weakly significant for CD4 count; when DSD referrals increased from 20-30%, the probability of having a CD4 count and VL test increased by 0.97% (95% CI: -0.27,2.58%) and 1.35% (95% CI: 0.11,2.95%) respectively. We found no evidence of an association with DSD and retention. Conclusions: In the first study of this topic, increases in clinic DSD referrals were associated with small improvements in care. With full DSD scale-up, programmatically meaningful effects could be achieved.
- 25 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e905-e906
Cardiovascular Disease Risk in Low- and Middle-Income Countries: Better Data for Better Evidence
- 25 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e905-e906
Cardiovascular Disease Risk in Low- and Middle-Income Countries: Better Data for Better Evidence
- 16 March 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Recovery in BMD following recent repeat pregnancy and breastfeeding among African women with and without HIV
Women living with HIV (WLWH) in resource-limited settings have benefited greatly from antiretroviral therapy (ART). However, they have several risk factors that can affect their bone health including being female, high parity/breastfeeding, use of life-long ART, and HIV disease itself. This study assessed bone mineral density (BMD) among recently pregnant WLWH (WLWH-P), and compared BMD changes over 3 yr with WLWH who were not pregnant (WLWH-NP) and with recently pregnant HIV-negative women (HIV-neg-P). We co-enrolled 104 WLWH-P from an ongoing cohort study in Malawi and Uganda, and used linear mixed models to compare standardized BMD values over 30-36 mo with 109 HIV-neg-P women matched for age-group/parity, and 99 age-group/parity matched WLWH who did not plan to become pregnant over 36 mo. BMD was assessed via DXA at baseline, 12, 24, and 30-36 mo. At baseline, median age of WLWH was 33 yr with HIV-neg-P being 32 yr. 91.4% of WLWH-P, and 87.9% of WLWH-NP were on Tenofovir-ART regimens. At baseline, 12, 24, and 30-36 mo postpartum, WLWH-P had lower mean standardized BMD values for FN, LS, and TH compared to HIV-neg-P women, although differences were not statistically significant except for baseline TH. In conclusion, both groups demonstrated BMD increase to above baseline scores by 30-36 mo. For WLWH-P compared to WLWH-NP, mean standardized BMD values trended lower between baseline and 24 mo. Both WLWH-P and HIV-neg-P women showed BMD recovery to baseline for FN, LS, and TH by 30-36 mo postpartum. However, mean BMD standard-scores trended lower throughout follow-up for WLWH-P compared to HIV-neg-P women. WLWH-P and WLWH-NP women had similar BMD standardized scores by 30-36 mo. The BMD recovery results are encouraging, but longer follow-up is needed to assess fracture risk among older WLWH compared to HIV-negative women.
- 16 March 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Recovery in BMD following recent repeat pregnancy and breastfeeding among African women with and without HIV
Women living with HIV (WLWH) in resource-limited settings have benefited greatly from antiretroviral therapy (ART). However, they have several risk factors that can affect their bone health including being female, high parity/breastfeeding, use of life-long ART, and HIV disease itself. This study assessed bone mineral density (BMD) among recently pregnant WLWH (WLWH-P), and compared BMD changes over 3 yr with WLWH who were not pregnant (WLWH-NP) and with recently pregnant HIV-negative women (HIV-neg-P). We co-enrolled 104 WLWH-P from an ongoing cohort study in Malawi and Uganda, and used linear mixed models to compare standardized BMD values over 30-36 mo with 109 HIV-neg-P women matched for age-group/parity, and 99 age-group/parity matched WLWH who did not plan to become pregnant over 36 mo. BMD was assessed via DXA at baseline, 12, 24, and 30-36 mo. At baseline, median age of WLWH was 33 yr with HIV-neg-P being 32 yr. 91.4% of WLWH-P, and 87.9% of WLWH-NP were on Tenofovir-ART regimens. At baseline, 12, 24, and 30-36 mo postpartum, WLWH-P had lower mean standardized BMD values for FN, LS, and TH compared to HIV-neg-P women, although differences were not statistically significant except for baseline TH. In conclusion, both groups demonstrated BMD increase to above baseline scores by 30-36 mo. For WLWH-P compared to WLWH-NP, mean standardized BMD values trended lower between baseline and 24 mo. Both WLWH-P and HIV-neg-P women showed BMD recovery to baseline for FN, LS, and TH by 30-36 mo postpartum. However, mean BMD standard-scores trended lower throughout follow-up for WLWH-P compared to HIV-neg-P women. WLWH-P and WLWH-NP women had similar BMD standardized scores by 30-36 mo. The BMD recovery results are encouraging, but longer follow-up is needed to assess fracture risk among older WLWH compared to HIV-negative women.
- Open Access
- 4 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , e1232-e1241
Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa
Background: Integrase inhibitors, including dolutegravir, may increase risk of major adverse cardiovascular events (MACEs). However, limited data exists from low- and middle-income countries, where tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) has largely replaced tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TEE). Methods: We used de-identified data from a South African managed healthcare organization from people with HIV (PWH) without cardiovascular disease, who either initiated TEE or TLD between April 2020 and Dec 2023 (initiation cohort) or were receiving TEE in April 2020 and eligible for TLD (transition cohort). In the initiation cohort, we emulated a target trial using pooled logistic regression models with inverse probability of treatment weights and bootstrapped CIs to compare estimated 3-year MACE risk between TLD versus TEE. In the transition cohort, we used similar methods in 44 emulated monthly sequential trials, comparing MACE risk in people transitioned to TLD with those remaining on TEE. Results: In the initiation cohort, 7310 PWH initiated TLD (n = 3711) or TEE (n = 3599). Median follow-up was 21 months (IQR 10–33), with 18 MACEs with TLD (3-year risk 0.78%, 95% CI .38–1.11) and 28 with TEE (3-year risk 1.03%, 0.63–1.55; RR 0.75, 0.31–1.30; RD −0.25, −0.94–0.24). In the transition cohort, 22 338 people contributed to 2837 person-trials with TLD and 706 615 with TEE. Median follow-up was 25 months (14–36), with 19 MACEs with TLD (3-year risk 0.97%, 0.52–1.62) and 5420 with TEE (3-year risk 1.17%, 0.99–1.37; RR 0.83, 0.45–1.39; RD −0.20, −0.66–0.44). Conclusions: Among PWH in South Africa, we found no increased MACE with TLD.
- 4 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , e1232-e1241
Open AccessRisk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa
Background: Integrase inhibitors, including dolutegravir, may increase risk of major adverse cardiovascular events (MACEs). However, limited data exists from low- and middle-income countries, where tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) has largely replaced tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TEE). Methods: We used de-identified data from a South African managed healthcare organization from people with HIV (PWH) without cardiovascular disease, who either initiated TEE or TLD between April 2020 and Dec 2023 (initiation cohort) or were receiving TEE in April 2020 and eligible for TLD (transition cohort). In the initiation cohort, we emulated a target trial using pooled logistic regression models with inverse probability of treatment weights and bootstrapped CIs to compare estimated 3-year MACE risk between TLD versus TEE. In the transition cohort, we used similar methods in 44 emulated monthly sequential trials, comparing MACE risk in people transitioned to TLD with those remaining on TEE. Results: In the initiation cohort, 7310 PWH initiated TLD (n = 3711) or TEE (n = 3599). Median follow-up was 21 months (IQR 10–33), with 18 MACEs with TLD (3-year risk 0.78%, 95% CI .38–1.11) and 28 with TEE (3-year risk 1.03%, 0.63–1.55; RR 0.75, 0.31–1.30; RD −0.25, −0.94–0.24). In the transition cohort, 22 338 people contributed to 2837 person-trials with TLD and 706 615 with TEE. Median follow-up was 25 months (14–36), with 19 MACEs with TLD (3-year risk 0.97%, 0.52–1.62) and 5420 with TEE (3-year risk 1.17%, 0.99–1.37; RR 0.83, 0.45–1.39; RD −0.20, −0.66–0.44). Conclusions: Among PWH in South Africa, we found no increased MACE with TLD.
- Open Access
Quality assessment of data for decentralised antiretroviral therapy referrals and laboratory results in the South African national electronic HIV management register TIER.Net
Three Interlinked Electronic Register (TIER.Net) is South Africa’s national electronic HIV patient database, used to monitor antiretroviral therapy (ART) delivery and laboratory results. However, few published evaluations have quantified TIER.Net data quality relative to national sources. We aimed to evaluate how well decentralised ART referral and laboratory result data are captured in TIER.Net. We conducted a retrospective analysis comparing TIER.Net to national electronic health systems. For decentralised ART, we used de-identified data from 56 clinics in eThekwini (2020-2023) and compared the annual number of TIER.Net decentralised ART referrals to ART prescriptions in the Synchronised National Communication in Health (SyNCH) database. For laboratory data, we used de-identified records from 103 clinics in KwaZulu-Natal (2015-2022) and compared the annual number of TIER.Net viral load (VL) and CD4 tests with the number in National Health Laboratory Service (NHLS). The proportion of SyNCH decentralised ART prescriptions and NHLS VL and CD4 counts captured in TIER.Net were calculated by clinic, and trends were assessed using linear mixed-effects models (LMMs). The median proportion of SyNCH decentralised ART prescriptions captured in TIER.Net was 104.4% (IQR: 99.85-115.1 % ) in 2020 and 102.44% (IQR: 100.5-104.5%) in 2023. The LMM estimated an annual decrease of 2.8% (95% CI: -4.8; -0.9%). The median proportion of NHLS VLs captured in TIER.Net was 85.7% (IQR: 70.0-97.9%) in 2015 and 99.1% (IQR: 94.5-102.5%) in 2022. The LMM estimated an annual increase of 1.8% (95% CI: 1.4-2.1%). The median proportion of NHLS CD4s captured in TIER.Net was 74.3% (IQR: 63.9-85.4%) in 2015 and 80.1% (IQR: 68.4-89.1%) in 2022. The LMM estimated no statistically significant trend over time (-0.08%, 95% CI: -0.6; 0.4%). Reassuringly, capture of TIER.Net for decentralised ART and VL data has improved to near 100%, but CD4 count capture remains sub-optimal, highlighting strengths and limitations of conducting analyses with this critical HIV programme database.
Open AccessQuality assessment of data for decentralised antiretroviral therapy referrals and laboratory results in the South African national electronic HIV management register TIER.Net
Three Interlinked Electronic Register (TIER.Net) is South Africa’s national electronic HIV patient database, used to monitor antiretroviral therapy (ART) delivery and laboratory results. However, few published evaluations have quantified TIER.Net data quality relative to national sources. We aimed to evaluate how well decentralised ART referral and laboratory result data are captured in TIER.Net. We conducted a retrospective analysis comparing TIER.Net to national electronic health systems. For decentralised ART, we used de-identified data from 56 clinics in eThekwini (2020-2023) and compared the annual number of TIER.Net decentralised ART referrals to ART prescriptions in the Synchronised National Communication in Health (SyNCH) database. For laboratory data, we used de-identified records from 103 clinics in KwaZulu-Natal (2015-2022) and compared the annual number of TIER.Net viral load (VL) and CD4 tests with the number in National Health Laboratory Service (NHLS). The proportion of SyNCH decentralised ART prescriptions and NHLS VL and CD4 counts captured in TIER.Net were calculated by clinic, and trends were assessed using linear mixed-effects models (LMMs). The median proportion of SyNCH decentralised ART prescriptions captured in TIER.Net was 104.4% (IQR: 99.85-115.1 % ) in 2020 and 102.44% (IQR: 100.5-104.5%) in 2023. The LMM estimated an annual decrease of 2.8% (95% CI: -4.8; -0.9%). The median proportion of NHLS VLs captured in TIER.Net was 85.7% (IQR: 70.0-97.9%) in 2015 and 99.1% (IQR: 94.5-102.5%) in 2022. The LMM estimated an annual increase of 1.8% (95% CI: 1.4-2.1%). The median proportion of NHLS CD4s captured in TIER.Net was 74.3% (IQR: 63.9-85.4%) in 2015 and 80.1% (IQR: 68.4-89.1%) in 2022. The LMM estimated no statistically significant trend over time (-0.08%, 95% CI: -0.6; 0.4%). Reassuringly, capture of TIER.Net for decentralised ART and VL data has improved to near 100%, but CD4 count capture remains sub-optimal, highlighting strengths and limitations of conducting analyses with this critical HIV programme database.